Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04553770
Title Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center

breast carcinoma


Trastuzumab deruxtecan

Anastrozole + Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.